Abstract
In a first study, we identified signatures of 3mRNAs (semaphorin3D [SEMA3D], cytokeratin16 [KRT16] and UL16binding protein2 [ULBP2]) associated to response to a cisplatin-vinorelbin chemotherapy and to survival of advanced non-small cell lung cancers (NSCLC). The aim of this study was to develop immunohistochemistry tests for KRT16, ULBP2and SEMA3D and to test proteins expression for prediction of response and survival in biopsies of the same patients. We were not able to reproduce by the protein expression study the signature predicting response to chemotherapy in advanced NSCLC. We highlight the difficulties of translational research in thoracic oncology emphasizing the complexity in obtaining adequate tissue samples and the difficulties in conduction and transposing in routine practice high throughput technique for transcriptomic analyses.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
